Loading…

Physician and facility drivers of spending variation in locoregional prostate cancer

Background Prostate cancer is the most common male cancer, with a wide range of treatment options. Payment reform to reduce unnecessary spending variation is an important strategy for reducing waste, but its magnitude and drivers within prostate cancer are unknown. Methods In total, 38,971 men aged...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2020-04, Vol.126 (8), p.1622-1631
Main Authors: Rodin, Danielle, Chien, Alyna T., Ellimoottil, Chad, Nguyen, Paul L., Kakani, Pragya, Mossanen, Matthew, Rosenthal, Meredith, Landrum, Mary Beth, Sinaiko, Anna D.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3939-92088f9eb1a66656b08151b1f46b63a519ddb5ccdfa63caa38eb72b32da4a0c73
cites cdi_FETCH-LOGICAL-c3939-92088f9eb1a66656b08151b1f46b63a519ddb5ccdfa63caa38eb72b32da4a0c73
container_end_page 1631
container_issue 8
container_start_page 1622
container_title Cancer
container_volume 126
creator Rodin, Danielle
Chien, Alyna T.
Ellimoottil, Chad
Nguyen, Paul L.
Kakani, Pragya
Mossanen, Matthew
Rosenthal, Meredith
Landrum, Mary Beth
Sinaiko, Anna D.
description Background Prostate cancer is the most common male cancer, with a wide range of treatment options. Payment reform to reduce unnecessary spending variation is an important strategy for reducing waste, but its magnitude and drivers within prostate cancer are unknown. Methods In total, 38,971 men aged ≥66 years with localized prostate cancer who were enrolled in Medicare fee‐for‐service and were included in the Surveillance, Epidemiology, and End Results‐Medicare database from 2009 to 2014 were included. Multilevel linear regression with physician and facility random effects was used to examine the contributions of urologists, radiation oncologists, and their affiliated facilities to variation in total patient spending in the year after diagnosis within geographic region. The authors assessed whether spending variation was driven by patient characteristics, disease risk, or treatments. Physicians and facilities were sorted into quintiles of adjusted patient‐level spending, and differences between those that were high‐spending and low‐spending were examined. Results Substantial variation in spending was driven by physician and facility factors. Differences in cancer treatment modalities drove more variation across physicians than differences in patient and disease characteristics (72% vs 2% for urologists, 20% vs 18% for radiation oncologists). The highest spending physicians spent 46% more than the lowest and had more imaging tests, inpatient care, and radiotherapy spending. There were no differences across spending quintiles in the use of robotic surgery by urologists or the use of brachytherapy by radiation oncologists. Conclusions Significant differences were observed for patients with similar demographics and disease characteristics. This variation across both physicians and facilities suggests that efforts to reduce unnecessary spending must address decision making at both levels. In an evaluation of the drivers of spending variation in the treatment of localized prostate cancer, the highest spending urologists and radiation oncologists spent 46% more and 43% more, respectively, than the lowest on men with similar individual and disease characteristics. Differences in primary treatment modalities and discretionary decision making for similar patients are the most important drivers of spending variation, and, to improve value, interventions should target decision making along the primary treatment pathway and should be directed at both individual physicia
doi_str_mv 10.1002/cncr.32719
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2383458566</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2383458566</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3939-92088f9eb1a66656b08151b1f46b63a519ddb5ccdfa63caa38eb72b32da4a0c73</originalsourceid><addsrcrecordid>eNp9kF1LwzAUhoMobk5v_AES8E7oTJo2bS-l-AVDRSZ4F04-OjO6dibdpP_ezE4vvTq88PCclxehc0qmlJD4WjXKTVmc0eIAjSkpsojQJD5EY0JIHqUJex-hE--XIWZxyo7RiNEiy0hOx2j-8tF7qyw0GBqNK1C2tl2PtbNb4zxuK-zXptG2WeAtOAudbRtsG1y3qnVmERLUeO1a30FnsIJGGXeKjiqovTnb3wl6u7udlw_R7Pn-sbyZRYoVrIiKmOR5VRhJgXOechkapVTSKuGSM0hpobVMldIVcKYAWG5kFksWa0iAqIxN0OXgDf8_N8Z3YtluXCjkRcxylqR5ynmgrgZKhZbemUqsnV2B6wUlYjeg2A0ofgYM8MVeuZEro__Q38UCQAfgy9am_0clyqfydZB-A1kUfCc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2383458566</pqid></control><display><type>article</type><title>Physician and facility drivers of spending variation in locoregional prostate cancer</title><source>Wiley</source><source>EZB Electronic Journals Library</source><creator>Rodin, Danielle ; Chien, Alyna T. ; Ellimoottil, Chad ; Nguyen, Paul L. ; Kakani, Pragya ; Mossanen, Matthew ; Rosenthal, Meredith ; Landrum, Mary Beth ; Sinaiko, Anna D.</creator><creatorcontrib>Rodin, Danielle ; Chien, Alyna T. ; Ellimoottil, Chad ; Nguyen, Paul L. ; Kakani, Pragya ; Mossanen, Matthew ; Rosenthal, Meredith ; Landrum, Mary Beth ; Sinaiko, Anna D.</creatorcontrib><description>Background Prostate cancer is the most common male cancer, with a wide range of treatment options. Payment reform to reduce unnecessary spending variation is an important strategy for reducing waste, but its magnitude and drivers within prostate cancer are unknown. Methods In total, 38,971 men aged ≥66 years with localized prostate cancer who were enrolled in Medicare fee‐for‐service and were included in the Surveillance, Epidemiology, and End Results‐Medicare database from 2009 to 2014 were included. Multilevel linear regression with physician and facility random effects was used to examine the contributions of urologists, radiation oncologists, and their affiliated facilities to variation in total patient spending in the year after diagnosis within geographic region. The authors assessed whether spending variation was driven by patient characteristics, disease risk, or treatments. Physicians and facilities were sorted into quintiles of adjusted patient‐level spending, and differences between those that were high‐spending and low‐spending were examined. Results Substantial variation in spending was driven by physician and facility factors. Differences in cancer treatment modalities drove more variation across physicians than differences in patient and disease characteristics (72% vs 2% for urologists, 20% vs 18% for radiation oncologists). The highest spending physicians spent 46% more than the lowest and had more imaging tests, inpatient care, and radiotherapy spending. There were no differences across spending quintiles in the use of robotic surgery by urologists or the use of brachytherapy by radiation oncologists. Conclusions Significant differences were observed for patients with similar demographics and disease characteristics. This variation across both physicians and facilities suggests that efforts to reduce unnecessary spending must address decision making at both levels. In an evaluation of the drivers of spending variation in the treatment of localized prostate cancer, the highest spending urologists and radiation oncologists spent 46% more and 43% more, respectively, than the lowest on men with similar individual and disease characteristics. Differences in primary treatment modalities and discretionary decision making for similar patients are the most important drivers of spending variation, and, to improve value, interventions should target decision making along the primary treatment pathway and should be directed at both individual physicians and facilities.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.32719</identifier><identifier>PMID: 31977081</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Brachytherapy ; cancer cost of care ; Cancer therapies ; Decision making ; Demography ; Epidemiology ; Government programs ; health economics ; Health risks ; health services research ; Medical treatment ; Medicare ; Oncology ; Patients ; Physicians ; practice variation ; Prostate cancer ; Radiation ; Radiation therapy ; Robotic surgery ; Surgery ; Urology ; Variation</subject><ispartof>Cancer, 2020-04, Vol.126 (8), p.1622-1631</ispartof><rights>2020 American Cancer Society</rights><rights>2020 American Cancer Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3939-92088f9eb1a66656b08151b1f46b63a519ddb5ccdfa63caa38eb72b32da4a0c73</citedby><cites>FETCH-LOGICAL-c3939-92088f9eb1a66656b08151b1f46b63a519ddb5ccdfa63caa38eb72b32da4a0c73</cites><orcidid>0000-0001-8279-0621</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31977081$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rodin, Danielle</creatorcontrib><creatorcontrib>Chien, Alyna T.</creatorcontrib><creatorcontrib>Ellimoottil, Chad</creatorcontrib><creatorcontrib>Nguyen, Paul L.</creatorcontrib><creatorcontrib>Kakani, Pragya</creatorcontrib><creatorcontrib>Mossanen, Matthew</creatorcontrib><creatorcontrib>Rosenthal, Meredith</creatorcontrib><creatorcontrib>Landrum, Mary Beth</creatorcontrib><creatorcontrib>Sinaiko, Anna D.</creatorcontrib><title>Physician and facility drivers of spending variation in locoregional prostate cancer</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Background Prostate cancer is the most common male cancer, with a wide range of treatment options. Payment reform to reduce unnecessary spending variation is an important strategy for reducing waste, but its magnitude and drivers within prostate cancer are unknown. Methods In total, 38,971 men aged ≥66 years with localized prostate cancer who were enrolled in Medicare fee‐for‐service and were included in the Surveillance, Epidemiology, and End Results‐Medicare database from 2009 to 2014 were included. Multilevel linear regression with physician and facility random effects was used to examine the contributions of urologists, radiation oncologists, and their affiliated facilities to variation in total patient spending in the year after diagnosis within geographic region. The authors assessed whether spending variation was driven by patient characteristics, disease risk, or treatments. Physicians and facilities were sorted into quintiles of adjusted patient‐level spending, and differences between those that were high‐spending and low‐spending were examined. Results Substantial variation in spending was driven by physician and facility factors. Differences in cancer treatment modalities drove more variation across physicians than differences in patient and disease characteristics (72% vs 2% for urologists, 20% vs 18% for radiation oncologists). The highest spending physicians spent 46% more than the lowest and had more imaging tests, inpatient care, and radiotherapy spending. There were no differences across spending quintiles in the use of robotic surgery by urologists or the use of brachytherapy by radiation oncologists. Conclusions Significant differences were observed for patients with similar demographics and disease characteristics. This variation across both physicians and facilities suggests that efforts to reduce unnecessary spending must address decision making at both levels. In an evaluation of the drivers of spending variation in the treatment of localized prostate cancer, the highest spending urologists and radiation oncologists spent 46% more and 43% more, respectively, than the lowest on men with similar individual and disease characteristics. Differences in primary treatment modalities and discretionary decision making for similar patients are the most important drivers of spending variation, and, to improve value, interventions should target decision making along the primary treatment pathway and should be directed at both individual physicians and facilities.</description><subject>Brachytherapy</subject><subject>cancer cost of care</subject><subject>Cancer therapies</subject><subject>Decision making</subject><subject>Demography</subject><subject>Epidemiology</subject><subject>Government programs</subject><subject>health economics</subject><subject>Health risks</subject><subject>health services research</subject><subject>Medical treatment</subject><subject>Medicare</subject><subject>Oncology</subject><subject>Patients</subject><subject>Physicians</subject><subject>practice variation</subject><subject>Prostate cancer</subject><subject>Radiation</subject><subject>Radiation therapy</subject><subject>Robotic surgery</subject><subject>Surgery</subject><subject>Urology</subject><subject>Variation</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kF1LwzAUhoMobk5v_AES8E7oTJo2bS-l-AVDRSZ4F04-OjO6dibdpP_ezE4vvTq88PCclxehc0qmlJD4WjXKTVmc0eIAjSkpsojQJD5EY0JIHqUJex-hE--XIWZxyo7RiNEiy0hOx2j-8tF7qyw0GBqNK1C2tl2PtbNb4zxuK-zXptG2WeAtOAudbRtsG1y3qnVmERLUeO1a30FnsIJGGXeKjiqovTnb3wl6u7udlw_R7Pn-sbyZRYoVrIiKmOR5VRhJgXOechkapVTSKuGSM0hpobVMldIVcKYAWG5kFksWa0iAqIxN0OXgDf8_N8Z3YtluXCjkRcxylqR5ynmgrgZKhZbemUqsnV2B6wUlYjeg2A0ofgYM8MVeuZEro__Q38UCQAfgy9am_0clyqfydZB-A1kUfCc</recordid><startdate>20200415</startdate><enddate>20200415</enddate><creator>Rodin, Danielle</creator><creator>Chien, Alyna T.</creator><creator>Ellimoottil, Chad</creator><creator>Nguyen, Paul L.</creator><creator>Kakani, Pragya</creator><creator>Mossanen, Matthew</creator><creator>Rosenthal, Meredith</creator><creator>Landrum, Mary Beth</creator><creator>Sinaiko, Anna D.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0001-8279-0621</orcidid></search><sort><creationdate>20200415</creationdate><title>Physician and facility drivers of spending variation in locoregional prostate cancer</title><author>Rodin, Danielle ; Chien, Alyna T. ; Ellimoottil, Chad ; Nguyen, Paul L. ; Kakani, Pragya ; Mossanen, Matthew ; Rosenthal, Meredith ; Landrum, Mary Beth ; Sinaiko, Anna D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3939-92088f9eb1a66656b08151b1f46b63a519ddb5ccdfa63caa38eb72b32da4a0c73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Brachytherapy</topic><topic>cancer cost of care</topic><topic>Cancer therapies</topic><topic>Decision making</topic><topic>Demography</topic><topic>Epidemiology</topic><topic>Government programs</topic><topic>health economics</topic><topic>Health risks</topic><topic>health services research</topic><topic>Medical treatment</topic><topic>Medicare</topic><topic>Oncology</topic><topic>Patients</topic><topic>Physicians</topic><topic>practice variation</topic><topic>Prostate cancer</topic><topic>Radiation</topic><topic>Radiation therapy</topic><topic>Robotic surgery</topic><topic>Surgery</topic><topic>Urology</topic><topic>Variation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rodin, Danielle</creatorcontrib><creatorcontrib>Chien, Alyna T.</creatorcontrib><creatorcontrib>Ellimoottil, Chad</creatorcontrib><creatorcontrib>Nguyen, Paul L.</creatorcontrib><creatorcontrib>Kakani, Pragya</creatorcontrib><creatorcontrib>Mossanen, Matthew</creatorcontrib><creatorcontrib>Rosenthal, Meredith</creatorcontrib><creatorcontrib>Landrum, Mary Beth</creatorcontrib><creatorcontrib>Sinaiko, Anna D.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rodin, Danielle</au><au>Chien, Alyna T.</au><au>Ellimoottil, Chad</au><au>Nguyen, Paul L.</au><au>Kakani, Pragya</au><au>Mossanen, Matthew</au><au>Rosenthal, Meredith</au><au>Landrum, Mary Beth</au><au>Sinaiko, Anna D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Physician and facility drivers of spending variation in locoregional prostate cancer</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2020-04-15</date><risdate>2020</risdate><volume>126</volume><issue>8</issue><spage>1622</spage><epage>1631</epage><pages>1622-1631</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>Background Prostate cancer is the most common male cancer, with a wide range of treatment options. Payment reform to reduce unnecessary spending variation is an important strategy for reducing waste, but its magnitude and drivers within prostate cancer are unknown. Methods In total, 38,971 men aged ≥66 years with localized prostate cancer who were enrolled in Medicare fee‐for‐service and were included in the Surveillance, Epidemiology, and End Results‐Medicare database from 2009 to 2014 were included. Multilevel linear regression with physician and facility random effects was used to examine the contributions of urologists, radiation oncologists, and their affiliated facilities to variation in total patient spending in the year after diagnosis within geographic region. The authors assessed whether spending variation was driven by patient characteristics, disease risk, or treatments. Physicians and facilities were sorted into quintiles of adjusted patient‐level spending, and differences between those that were high‐spending and low‐spending were examined. Results Substantial variation in spending was driven by physician and facility factors. Differences in cancer treatment modalities drove more variation across physicians than differences in patient and disease characteristics (72% vs 2% for urologists, 20% vs 18% for radiation oncologists). The highest spending physicians spent 46% more than the lowest and had more imaging tests, inpatient care, and radiotherapy spending. There were no differences across spending quintiles in the use of robotic surgery by urologists or the use of brachytherapy by radiation oncologists. Conclusions Significant differences were observed for patients with similar demographics and disease characteristics. This variation across both physicians and facilities suggests that efforts to reduce unnecessary spending must address decision making at both levels. In an evaluation of the drivers of spending variation in the treatment of localized prostate cancer, the highest spending urologists and radiation oncologists spent 46% more and 43% more, respectively, than the lowest on men with similar individual and disease characteristics. Differences in primary treatment modalities and discretionary decision making for similar patients are the most important drivers of spending variation, and, to improve value, interventions should target decision making along the primary treatment pathway and should be directed at both individual physicians and facilities.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31977081</pmid><doi>10.1002/cncr.32719</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8279-0621</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 2020-04, Vol.126 (8), p.1622-1631
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_journals_2383458566
source Wiley; EZB Electronic Journals Library
subjects Brachytherapy
cancer cost of care
Cancer therapies
Decision making
Demography
Epidemiology
Government programs
health economics
Health risks
health services research
Medical treatment
Medicare
Oncology
Patients
Physicians
practice variation
Prostate cancer
Radiation
Radiation therapy
Robotic surgery
Surgery
Urology
Variation
title Physician and facility drivers of spending variation in locoregional prostate cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A25%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Physician%20and%20facility%20drivers%20of%20spending%20variation%20in%20locoregional%20prostate%20cancer&rft.jtitle=Cancer&rft.au=Rodin,%20Danielle&rft.date=2020-04-15&rft.volume=126&rft.issue=8&rft.spage=1622&rft.epage=1631&rft.pages=1622-1631&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.32719&rft_dat=%3Cproquest_cross%3E2383458566%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3939-92088f9eb1a66656b08151b1f46b63a519ddb5ccdfa63caa38eb72b32da4a0c73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2383458566&rft_id=info:pmid/31977081&rfr_iscdi=true